Campath - 1 H: Emerging Frontline Therapy in Chronic Lymphocytic Leukemia. This item is unavailable.Campath - 1 H: Emerging Frontline Therapy in Chronic Lymphocytic Leukemia

This is the only authoritative, detailed clinical reference on Campath-1H, which stands alone among monoclonal antibodies because its reciprocal antigen CD52 is expressed in diverse cell types, and its further potential for clinical practice in hemato-oncology in the treatment of B-cell chronic lymphocytic leukemia. It records the development and actions of Campath-1H, presents the unique clinical, immunological and molecular features of B-cell chronic lymphocytic leukemia, and explores the potential of Campath-1H as frontline therapy for patients with B-CLL. The book contains five main chapters on B-cell chronic lymphocytic leukemia, the road to remission (from single agent intervention to combination therapy and onward), monoclonal antibodies in cancer (the development of Campath-1H), Campath-1H in B-CLL (remissions of refractory disease), and the role of Campath-1H prior to bone marrow transplant in refractory B-CLL plus a concluding chapter on future perspectives.

'The book gives an excellent, up-to-date, concise, comprehensive and authoritative review of the role of Campath-1H in chronic lymphocytic leukemia by leading authorities in the area. A very useful book for anyone planning to use the drug for patient treatment in the clinical setting, and also those with a wider interest in B-CLL or monoclonal antibody therapy.' - S. Mulligan, Department of Heamatology, Concord Repatriation Hospital, Australia in Cancer Forum